Gilead Sciences Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One decreased by 21.1% to $15.00M in Q1 2026 compared to the prior quarter.
Higher values indicate a larger portion of the portfolio is liquid and available for reinvestment or cash needs in the short term.
This represents the amortized cost of debt securities in the available-for-sale portfolio that are scheduled to mature w...
Standard maturity bucket reporting for insurance investment portfolios.
other_available_for_sale_securities_debt_maturities_with_72951f| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.69B | $1.39B | $1.09B | $962.00M | $1.02B | $1.01B | $1.01B | $1.23B | $79.00M | $19.00M | $15.00M |
| QoQ Change | — | -17.6% | -21.5% | -11.8% | +5.8% | -1.2% | +0.8% | +21.6% | -93.6% | -75.9% | -21.1% |
| YoY Change | — | — | — | -43.0% | -26.8% | -7.8% | +5.4% | +21.1% | — | — | — |